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Introduction: Many women with a bipolar disorder are of reproductive age and will need to continue lithium
treatment during pregnancy. The teratogenic and perinatal effects of lithium are known, but not the long-
term effects of lithium on neurodevelopment of the children. This study investigates growth, neurological,
cognitive and behavioral development of children exposed to lithium in utero.
Method: In an observational retrospective cohort study 15 children who were exposed to lithium in utero
were investigated at 3–15 years of age. Neurological development was tested using the Hempel or Touwen
examination. Cognitive development was assessed with the Bayley Scales of Infant Development III, Wechsler
Preschool and Primary Scale of Intelligence or theWechsler Intelligence Scale for Children. Parents completed
the Child Behavior Checklist to assess behavioral development and a standard questionnaire about general
development of the child since birth.
Results: One child had signs of a minor neurological dysfunction, but without further clinical implications. The
results of the cognitive tests were within normal limits, although most children had lower scores on the per-
formance IQ subtest. Growth, behavior and general development were within the normal range.
Conclusions: Continuing lithium therapy during pregnancy did not cause adverse effects on growth, neurolog-
ical, cognitive and behavioral development of exposed children.
© 2011 Elsevier Ireland Ltd. Open access under the Elsevier OA license.1. Introduction
Since the 1950s lithium is the most important drug in the pharma-
cological treatment of bipolar disorder. Bipolar disorder is common in
women in their reproductive age, which raises the question whether
intrauterine exposure to lithium affects neurodevelopmental out-
come of exposed children [1]. Discontinuation of lithium use during
pregnancy is contraindicated as this is associated with a twofold
greater risk of recurrence of a new episode of mania or depression
[2–4].
Lithium entirely readily crosses the placenta and the fetus receives
100% of the drug during pregnancy. High serum lithium levels at de-
livery are associated with a higher incidence of neonatal complica-
tions and have led to interruption of lithium therapy or use of lower
doses of lithium shortly before delivery [5].
The risk of congenital disorders of children who received lithium
in utero has been extensively investigated. A retrospective analysisity Medical Center, J6-S, Albi-
31 71 5262957; fax: +31 71
oth be considered ﬁrst-author.
 the Elsevier OA license.of data from the Danish Register of Lithium Babies in 1976 suggested
a high risk of Ebstein's anomaly (6 out of 225 exposed children versus
an incidence of 1 in 20,000 in the general population) [6], but this
turned out to be a gross overestimation due to a voluntary reporting
bias. The Motherisk Program performed two studies on the potential
teratogenic effect of lithium and found a relative risk for all congenital
disorders of 1.2 and for cardiac disorders of 1.1 and no association of
lithium use with Ebstein's anomaly [7,8]. A review of the epidemio-
logic data by Cohen et al. concluded that the teratogenic risk of
ﬁrst-trimester lithium exposure is lower than previously suggested
[9].
Many case reports describe neonatal lithium toxicity which often
presents as a “ﬂoppy infant syndrome” characterized by lethargy,
poor sucking, tachypnea, tachycardia, respiratory distress syndrome,
cyanosis and hypotonie [10]. Other neonatal problems include struc-
tural and functional cardiovascular problems, macrosomia, hyperbi-
lirubinemia, diabetes insipidus, and hypothyreoidism [10]. However,
an elevated risk of these adaptation problems and complications has
never been signiﬁcantly proven and most of them are transient and
without long-term consequences [11].
Although lithium does not seem to cause major congenital disor-
ders, there is a realistic possibility of long-term effects on the devel-
oping fetal brain during pregnancy [12,13]. The ﬁrst trimester is the
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oping throughout pregnancy and highly vulnerable to the latent cog-
nitive and neurological impact of drugs [14]. Youngs et al.
investigated long-term effects of lithium on the developing rat brain
and found long-lasting increases in anxiety-like behavior [15]. Except
for a follow-up questionnaire reported by Schou, long-term effects of
exposure to lithium in utero have not been studied in humans [16,17].
This lack of knowledge causes fear in womenwho use lithium and are
pregnant, or are planning a pregnancy [18].
The objective of this study was to investigate growth and neuro-
logical, cognitive and behavioral development of children who were
exposed to lithium in utero.
2. Method
2.1. Participants
The Perinatal Center of the Leiden University Medical Center
(LUMC) prospectively collected perinatal data on all mothers treated
with lithium (target maintenance serum lithium levels 0.6–
0.8 mmol/L) for bipolar disorder during pregnancy and their children
in the period between 1-1-1994 and 31-12-2007. Mothers with a bi-
polar disorder without lithium therapy were not identiﬁed in the de-
ﬁned period. Twenty-one mothers of 30 children born alive in the
LUMC between 1-1-1994 and 31-12-2007 were asked by their psychi-
atrist or obstetrician for permission to examine their children for fol-
low-up purposes. The psychiatrist or obstetrician called the mothers
to inform them about the study and ask them if they wanted to par-
ticipate. If they agreed, information about the study and follow-up
questionnaires were sent and the physical and psychological exami-
nation scheduled. The ethics committee of the hospital approved
the study and informed consent was obtained from the parents.
2.2. Study design
Growth and neurological, cognitive and behavioral outcome of
lithium-exposed children were assessed using standard tests, validat-
ed in the Dutch population. Data collection was done during the neo-
natal period and between November 2008 and December 2009. The
visit of the children with one of their parents to the hospital lasted
about 4 h.
2.3. Assessments
2.3.1. Neonatal assessment
The neonatal database provided [1] data on the medical and ob-
stetric history of the mothers, including use of medications during
pregnancy, serum lithium values, method of delivery, and perinatal
complications, and [2] data collected during the 24 h observation of
each child after birth, including birth weight; 1 and 5 min Apgar
scores; umbilical cord blood lithium levels; chest X-ray, ECG, and
echocardiography (if indicated); blood glucose, serum electrolytes,
and thyroid function.
2.3.2. Developmental assessment and growth
Physical and mental development of the child was screened using
a questionnaire to be ﬁlled in by the mother. Items that were asked
were growth, illnesses, behavioral problems, motor problems and de-
velopmental milestones. Growth of the children was assessed by
measurement of height, weight and head circumference and plotted
in the Dutch growth curves.
2.3.3. Neurological examination
Children between 2 and 5 years of age were assessed according to
the Hempel examination [19]. Outcome of this test is divided into 3
groups: normal, simple minor neurological dysfunction (MND) whendysfunction is detected in 1 cluster, and complex MND when dysfunc-
tion is found inmore than 1 cluster. For older children the Touwen pro-
tocol for neurological examination was used [20,21]. Outcome for that
test is 0 (normal), 1 (simple MND), 2 (complex MND), 3 (Complex Pa-
thology, CP).
2.3.4. Cognitive testing
Cognition was assessed by a child psychologist. Children between
16 and 30 months old were tested with the Bayley Scales of Infant De-
velopment (BSID III) [22] and older children were tested with the
Wechsler Preschool and Primary Scale of Intelligence or the Wechsler
Intelligence Scale for Children (WPPSI/WISC) [23]. The BSID reports a
Developmental Score, the WPPSI/WISC consists of a verbal intelli-
gence quotient (VIQ), performance intelligence quotient (PIQ) and
total intelligence quotient (TIQ). All tests have a mean score of 100
and a standard deviation of 15.
2.3.5. Behavioral assessment
Behavioral development of the children was tested by having the
mothers complete the Child Behavior Checklist (CBCL) for children
from 1.5 to 5 or 6–18 years [24]. Outcome of this test consists of T-
values on 6 different areas of the DSM-IV: affective problems, anxiety
problems, attention deﬁcit/hyperactivity problems, oppositional deﬁ-
ant problems, conduct problems, pervasive problems (1.5–5 year old)
or somatic problems (6–18 year old). Results of these scores are di-
vided into 3 categories, with T-values of 50–64.5 being normal, 64.5
to 69.5 subclinical and 69.5–100 clinical.
2.3.6. Statistical analysis
Data are presented as means±standard deviation (SD) or as me-
dian (range).
3. Results
None of the 30 lithium-exposed children were born with congenital
anomalies known to be associated with maternal lithium use. Mean±
SD birth weight was 3384±510 g, mean gestational age was 38.0±
1.2 weeks and none of the children was asphyxiated (5 min Apgar
score b7) or needed respiratory support at birth. Seventeen out of 30
children were born by normal vaginal delivery. Ten children (of
whom ﬁve were seen for follow-up) showed signs of neonatal toxicity:
4 had respiratory symptoms, 4 nausea and vomiting (retching, refusal of
nutrition), 2 hypoglycemia, 1 hypotonia and 1 hyperbilirubinemia. Two
children had serum lithiumvalues N0.8 mmol/L, of whomone had signs
of neonatal toxicity. In addition to lithium, 9 out of 30 childrenwere ex-
posed to other psychotropic medications (4 were exposed to antide-
pressants, 4 to benzodiazepines and 1 to an antipsychotic drug). One
child had a ventricular septal defect with coarctation of the aorta and
underwent successful surgical repair. Serum electrolytes, renal function
and thyroid hormones were normal in all.
Six mothers (8 children) could not be reached for follow-up be-
cause they had moved without leaving a forwarding address or
moved out of the country, 3 mothers (5 children) refused participa-
tion and 2 mothers (2 children) were not available on test dates.
Ten mothers were left, with a total of 15 children, to participate in
the study. In Fig. 1 a ﬂowchart can be seen of participating children
and mothers.
Table 1 shows the baseline characteristics of the 15 children who
participated in the follow-up study. No signiﬁcant differences were
found in baseline characteristics comparing participating and non-
participating children in the follow-up study.
Results of the neurological and physical examinations are pre-
sented in Table 2. One child had a minor neurological dysfunction
(MND), but this result was without further clinical implications. In
all other cases no neurologic abnormalities were found. Growth mea-
surements were all within the normal range.
30 children
of 22 mothers
22 children
of 15 mothers
reached
8 children
of 6 mothers
not reached
17 children
of 12 mothers
agreed
5 children
of 3 mothers
refused
15 children
of 10 mothers
available
for participation
2 children
of 2 mothers
not available
on testdates
Fig. 1. Flowchart of participating children in follow-up study.
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Testing of cognition with WISC-III-NL, WPPSI-R and Bayley tests did
not demonstrate any abnormality. One child had a low VIQ and TIQ,
but the PIQ was normal. All other data were within the normal
range. Most children had a lower score on the performance tests, es-
pecially on the subtest Block patterns, but this was not a signiﬁcant
deprivation. The child tested with the WPPSI-R had above average
scores, so did one child tested with the Bayley test.
The results of the CBCL-questionnaire showed no abnormalities in
the areas of Affective Problems, ADH, Conduct Problems and Perva-
sive Disorders and all scores were within the normal range. In the
area of Anxiety Problems two children scored in the subclinical
range, one of whom also scored in the subclinical range in the area
of Somatic Problems. One child was in the subclinical range in the
area of Oppositional Problems.
Developmental milestones were normal in all children. Parents
mentioned hyperactivity and concentration problems in 3 children.
Medical histories frequently reported viral upper airway infections,
eczema in 4 children and allergies in 2. Two children received phys-
ical therapy when they were 1.5 to 4 years old to improve their
gross motor skills. One child had transient motor problems at the
age of 7.Table 1
Baseline characteristics of children who participated in the follow-up study.
Patient
#
Gravida/
para
Age of
mother
(years)
Other
psychotropic
medication
Gestational
age (weeks)
Delivery*
1 G1P0 34 39 VE
2 G2P1 37 39 VE
3 G1P0 34 39 VE
4 G2P1 36 38 V
5 G1P0 37 38 V
6 G2P1 28 Fluoxetine 37 V
7 G1P0 36 37 VE
8 G1P0 29 40 VE
9 G2P1 40 40 CS
10 G1P0 32 40 CS
11 G2P0 35 Haloperidol 39 VE
12 G2P1 31 38 V
13 G3P1 38 Nortriptyline 36 V
14 G2P1 36 Lorazepam 39 CS
15 G1P0 35 37 V
*: V: vaginal delivery; VE: vacuum extraction; CS: cesarean section.4. Discussion
This study reports the long-term outcome of 15 children who were
exposed to lithium in utero andwere not breastfed. Neurological screen-
ing and growthmeasurements did not show signiﬁcant abnormalities in
the children, all were well within the normal range. Intelligence tests
detected lower scores in the performance tests, especially in the Block
pattern subtest, in nearly all children, but the difference with a control
general population was not signiﬁcant. Motor and behavioral develop-
ment showedno signiﬁcant abnormalities, based on the CBCL and devel-
opmental questionnaire.
The only study on follow-up of lithium exposed children was done
by Schou in 1976 [16]. In this follow-up study a questionnaire was
sent to the psychiatrist or the general practitioner of the mothers of
60 children who had been exposed to lithium in utero. These doctors
were requested to ask the mothers if any problems in physical or
mental development had occurred in the lithium-exposed children
and their non-lithium-exposed siblings who served as a control
group. No signiﬁcant differences were found between both groups.
However, this study was based on the subjective report of the
mothers, never a study was done where a pediatrician and a psychol-
ogist examined the children. Our study comprised growth measure-
ments and formal testing of neurological, cognitive and behavioral
outcome in 15 children 3–15 years of age and shows that outcome
of these children is indeed within normal limits.
Limitations of this study are the relatively small sample size,
lack of a suitable control group, and use of other psychotropic med-
ications. Because of the observational character of the study, no
speciﬁc hypothesis was formulated in advance. Small differences
may be difﬁcult to detect due to the small group of children tested
and the intrinsic limitations of the standard screening instruments
for behavioral development [25]. A possible negative ﬁnding may
be the lower scores on the performance IQ (PIQ) tests, but further
and more speciﬁc research needs to be done on this subject. As
the lower scores of PIQ were not statistically signiﬁcant, it was
not necessary to investigate the role of potential confounding fac-
tors on cognitive development (maternal IQ, socioeconomic status,
use of alcohol and tobacco). No suitable control group could be
found, because it is almost impossible to identify children who
were raised in the same situation and family, but without in utero
exposure to lithium. This type of controls was not available to us.
However, normal values of tests for psychological and behavioral
development are based on a large cohort of children from the gen-
eral population, which functions like a control group.Gender
(Male,
female)
Birth
weight
(g)
Apgar scores Lithium cord
blood level N
0.8 mmol/L
Neonatal
toxicity
1 min 5 min
F 3820 8 9
F 4740 9 10 X
M 3720 9 10
F 2870 10 10 X
M 3130 8 9 X
F 3500 8 9
M 3240 8 9
M 3655 5 8
F 3665 8 9
M 3766 8 9 X
F 3585 8 10
F 3835 10 10
F 2675 7 9
F 3715 9 9 X
F 3290 9 10 X X
Table 2
Neurological and growth assessments and psychological examinations at follow-up.
Patient
#
Age
(years)
Neurological and growth assessment Psychological examination
Neurological
outcome1
Height
(cm)
Weight
(kg)
Head circum
ference (cm)
WISC-III-NL and WPPSI-R2 BSID-III
VIQ PIQ TIQ DS 95% CI
1 15 Normal 183.7 62.8 55 122 105 116
2 13 Normal 172 49.3 54 108 99 105
3 11 Normal 154 42.0 57 115 96 107
4 10 Normal 147.5 36.2 55 122 118 123
5 9 Normal 128.7 24.9 52 103 91 97
6 9 Normal 133.5 26.8 51 83 88 84
7 7 Simple MND 132.8 26.5 53 107 107 108
8 8 Normal 132 27 53 106 86 96
9 7 Normal 125.2 22.5 51 105 88 96
10 6 Normal 124 24.8 54 122 110 119
11 6 Normal 119 24.3 51 107 99 104
12 6 Normal 118 22 50 126 121 128
13 4 Normal 98 15.5 49 109 137 126
14 3 Normal 96.5 15.5 50 139 126–139
15 3 Normal 99.4 16.4 48.6 105 97–113
1. Neurological and growth examination→Normal: normal neurological development. MND: minor neurological dysfunction. Patients 1–9: Touwen exam; patients 10–15: Hempel
exam.
2. Psychological examination→WISC-III-NL: Wechsler Intelligence Scale for Children (patients 1–12); WPPSI-R: Wechsler Preschool and Primary Scale of Intelligence (patient 13);
BSID-III Bayley Scales of Infant Development.
Outcomes→VIQ: verbal intelligence quotient; PIQ: performance intelligence quotient; TIQ: total intelligence quotient; DS: developmental score; 95% CI: 95% conﬁdence interval.
378 N.M. van der Lugt et al. / Early Human Development 88 (2012) 375–378Based on our results we conclude that the children are developing
normally after being exposed to lithium in utero and that no major
developmental problems have evolved. This supports the thesis that
continuing lithium therapy during pregnancy does not adversely af-
fect the development of a child, and that it is rather safe to do so.
This information may provide the counseling doctor and the bipolar
womanmore conﬁdence in planning a safe pregnancy and continuing
lithium treatment.
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